.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Fish and Richardson
Mallinckrodt
Boehringer Ingelheim
McKesson
Farmers Insurance
Queensland Health
US Army
Colorcon
Chinese Patent Office

Generated: September 22, 2017

DrugPatentWatch Database Preview

Ge Healthcare Company Profile

« Back to Dashboard

What is the competitive landscape for GE HEALTHCARE, and when can generic versions of GE HEALTHCARE drugs launch?

GE HEALTHCARE has fifty-five approved drugs.

There are six US patents protecting GE HEALTHCARE drugs.

There are one hundred and five patent family members on GE HEALTHCARE drugs in thirty countries.

Summary for Applicant: Ge Healthcare

Patents:6
Tradenames:61
Ingredients:43
NDAs:55
Drug Master File Entries: (click here to view)5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
NEOSCAN
gallium citrate ga-67
INJECTABLE;INJECTION017655-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
ISOPAQUE 280
calcium; meglumine; metrizoic acid
INJECTABLE;INJECTION017506-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
TESLASCAN
mangafodipir trisodium
INJECTABLE;INJECTION020652-001Nov 26, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
SODIUM POLYPHOSPHATE-TIN KIT
technetium tc-99m polyphosphate kit
INJECTABLE;INJECTION017664-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Ge Healthcare
METASTRON
strontium chloride sr-89
INJECTABLE;INJECTION020134-001Jun 18, 1993APRXYesYes► Subscribe► Subscribe► Subscribe
Ge Healthcare
SODIUM IODIDE I 123
sodium iodide i-123
CAPSULE;ORAL017630-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION020123-001Jan 8, 1993► Subscribe► Subscribe
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION022066-001Sep 5, 2007► Subscribe► Subscribe
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION022066-002Sep 5, 2007► Subscribe► Subscribe
Ge Healthcare
MPI DMSA KIDNEY REAGENT
technetium tc-99m succimer kit
INJECTABLE;INJECTION017944-001May 18, 1982► Subscribe► Subscribe
Ge Healthcare
OMNIPAQUE 180
iohexol
SOLUTION;INJECTION, ORAL, RECTAL018956-001Dec 26, 1985► Subscribe► Subscribe
Ge Healthcare
AMIPAQUE
metrizamide
INJECTABLE;INJECTION017982-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION020123-001Jan 8, 1993► Subscribe► Subscribe
Ge Healthcare
OMNIPAQUE 350
iohexol
SOLUTION;INJECTION, ORAL018956-004Dec 26, 1985► Subscribe► Subscribe
Ge Healthcare
TESLASCAN
mangafodipir trisodium
INJECTABLE;INJECTION020652-001Nov 26, 1997► Subscribe► Subscribe
Ge Healthcare
INDIUM IN 111 OXYQUINOLINE
indium in-111 oxyquinoline
INJECTABLE;INJECTION019044-001Dec 24, 1985► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ge Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,875,420 Method of ultrasound imaging► Subscribe
7,854,920Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
5,393,524 Methods for selecting and using gases as ultrasound contrast media► Subscribe
5,558,854 Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas► Subscribe
8,404,213Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
5,558,094 Methods for using persistent gases as ultrasound contrast media► Subscribe
9,134,328Methods of using benzothiazole derivative compounds and compositions► Subscribe
6,620,404 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
5,666,526 Method and system for supporting scrollable, updatable database queries► Subscribe
6,156,292 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ge Healthcare Drugs

Country Document Number Estimated Expiration
Taiwan210957► Subscribe
Spain2145011► Subscribe
Brazil1100167► Subscribe
Japan2006522104► Subscribe
Hungary218018► Subscribe
Canada2694084► Subscribe
Portugal1334091► Subscribe
Poland360550► Subscribe
World Intellectual Property Organization (WIPO)0216333► Subscribe
Luxembourg92634► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ge Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90009-5Sweden► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
2014 00050Denmark► SubscribePRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
/1997Austria► SubscribePRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
90018-6Sweden► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
00125Netherlands► SubscribePRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
00724Netherlands► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
15/004Ireland► SubscribePRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Julphar
Fuji
Teva
Novartis
Chinese Patent Office
Boehringer Ingelheim
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot